Columbia University

Technology Ventures

Latest News

A new study by the Milken Institute ranks Columbia University as number two in the country for commercializing science and technology emerging from university research labs.

TheraPten Biosciences Inc., a Canadian biotechnology company, has entered into an exclusive licensing agreement with Columbia University on two globally issued patent families covering PTEN-L, a naturally-occurring tumor suppressor protein.

Applied Therapeutics Inc., today announced the closing of its Series A financing round. The financing was led by Alexandria Venture Investments alongside E Squared Capital Management, Franklin Berger, ETP Global Fund and Syno Capital. Joel S.

Doctor Rebecca Brachman has been selected as a TED Fellow, joining a class of 15 change-makers from around the world who will deliver a talk on the TED stage this April in Vancouver.

Lin Bioscience and Columbia Technology Ventures announced that Lin Bioscience has licensed the intellectual property portfolio and development program for a promising first-in-class medication intended to slow or halt the progression of atrophic "Dry" Age-Related Macular Degeneration (AMD).  

Fortress Biotech, Inc. announced the formation of a new subsidiary company, Caelum Biosciences, Inc., to advance the development of CAEL‐ 101 (11‐1F4) for the treatment of amyloid light chain (“AL”) amyloidosis.

Mannheim/Wetzlar, Germany. Leica Microsystems CMS GmbH has entered into an exclusive, worldwide licensing agreement with Columbia University in New York to commercialize SCAPE microscopy for Life Science applications.